Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients

Table 5

Multivariate analysis of clinicopathological variables of FN.

Variables	Before propensity matching			After propensity matching
	OR	95% CI		OR	95% CI
Age	0.985	0.963–1.007	0.182	0.995	0.979–1.014	0.590
Chemotherapy regimens
1	1	—	—	1	—	—
2	1.797	0.585–5.514	0.306	0.785	0.321–1.918	0.595
3	6.433	2.612–15.844	0.000052	4.304	2.641–7.015	<0.0001
4	2.516	0.942–6.721	0.066	1.917	1.035–3.552	0.039
TNM stage
I	1	—	—	1	—	—
II	0.895	0.542–1.478	0.665	0.925	0.613–1.396	0.711
III and IV	0.897	0.457–1.757	0.750	0.690	0.383–1.244	0.217
Neoadjuvant chemotherapy	0.710	0.426–1.184	0.190	1.519	0.916–2.522	0.106
ER	0.588	0.289–1.195	0.142	0.544	0.291–1.014	0.055
PR	1.404	0.720–2.738	0.319	2.631	1.418–4.882	0.002
HER-2	0.803	0.464–1.391	0.434	1.009	0.622–1.637	0.970
Ki67	0.946	0.589–1.520	0.819	1.182	0.812–1.721	0.383
TCM treatment	0.166	0.098–0.280	<0.0001	0.184	0.122–0.279	<0.0001

Chemotherapy: 1: the chemotherapy regimens contain AC/EC (Adriamycin or epirubicin, Cyclophosphamide) and CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil). 2: the chemotherapy regimens contain TC (paclitaxel or docetaxel, Cyclophosphamide) and T (paclitaxel or docetaxel). 3: the chemotherapy regimens contain anthracyclines combined with paclitaxel or docetaxel: TAC/TEC (paclitaxel or docetaxel, Cyclophosphamide, and Adriamycin or epirubicin); TA/TE (paclitaxel or docetaxel, Adriamycin or epirubicin). 4: the chemotherapy regimens contain anthracyclines followed by paclitaxel or docetaxel: AC/EC (Adriamycin or epirubicin, Cyclophosphamide); CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil), followed with T or TH (paclitaxel or docetaxel, Herceptin). FN: body temperature ≥38.2°C and absolute neutrophil count <0.5 × 10⁹/L on the same day of the fever or the day after.